Given the limited response rates to current immune checkpoint inhibitors in HCC [43], therapeutic strategies targeting the STT3A-FCN3-β-catenin axis may provide new treatment options for advanced HCC patients. This evidence concerns the gene FCN3 and hepatocellular carcinoma.